

Grifols – Withdrawal of Gamunex-C® (immune globulin [human])

- On December 16, 2019, [Grifols announced](#) a voluntary, consumer-level withdrawal of one lot of [Gamunex-C \(immune globulin \[human\]\)](#) injection due to a higher rate of allergic/hypersensitivity type reactions, a small number of which were considered medically significant.
- The withdrawn Gamunex-C was distributed in the U.S. and had a market release date of July 29, 2019.

Product Description	NDC #	Lot # (Expiration Date)
Gamunex-C 10%	13533-800-71	A4GKD00232 (6/8/2022)

- Gamunex-C is indicated for the treatment of primary humoral immunodeficiency in patients 2 years of age and older; idiopathic thrombocytopenic purpura in adults and children; and chronic inflammatory demyelinating polyneuropathy in adults.
- Per Grifols, hypersensitivity and anaphylactic/anaphylactoid reactions are a known risk with IVIG products.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to the withdrawn Gamunex-C injection.
- Anyone with an existing inventory of the withdrawn product should stop use and quarantine the product immediately.
- For more information regarding this withdrawal, contact Grifols US Clinical Communications at **1-800-520-2807**.